Human Chorionic Gonadotropic Market Size, Share, Industry, Forecast and outlook (2024-2031)

Human Chorionic Gonadotropic Market is Segmented By Technology (Natural Source Extraction, Recombinant Technology), By Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, Others), By End-User (Fertility Clinics, Research institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Human Chorionic Gonadotropic Market Overview

Human Chorionic Gonadotropic Market is Expected to reach at a high at a CAGR of 7.3% during the forecast period (2024-2031).     

The placenta secretes human chorionic gonadotropin hormone (HCG) after a fertilized zygote is implanted in the uterus. The hormone also aids in the stimulation of egg release from the ovary and maintains optimal egg development. HCG is mostly used to stimulate ovulation in women undergoing infertility therapy. It is also used in males to improve sperm count and in young boys with pituitary gland abnormalities or other conditions that prevent the testicles from naturally dropping down into the scrotum. HCG is normally given as an injection into a muscle beneath the skin.

Human Chorionic Gonadotropic Market Scope

To Get a Free Sample Click here

Human Chorionic Gonadotropic Market Dynamics

The increase is related to the rising global burden of infertility and hypogonadism. Furthermore, rising awareness of the HGC among healthcare professionals and patients and new product launches are expected to drive market growth throughout the forecast period. Furthermore, choriocarcinoma, seminoma, germ cell tumors, and other cancers employ human chorionic gonadotropin as a marker.Furthermore, ongoing research and development in gonadotropin extraction and processing and favorable government and non-government initiatives are likely to boost demand for human chorionic gonadotropin products around the world.

The increase in prevalance of infertility and hypogonadism in the market will drive the market growth

According to the CDC, 7.3 M women aged 15 to 44 received infertility therapies in 2016. Furthermore, 6.7 percent of married women aged 15 to 44 were infertile. According to Azura Vascular Care, around 17% of couples in the United States struggle with infertility, with male infertility accounting for 30% of cases. These figures indicate a high demand for infertility therapies like HCG for women to conceive a child. Pituitary gland problems claimed the lives of roughly 205 people in 2019, according to a HealthGrove survey, with white men accounting for the majority of the deaths.

The need for human chorionic gonadotropin hormone is driven by pituitary diseases resulting in a high death rate. Other variables such as endometriosis, hormonal imbalance, polycystic ovary syndrome, and others are projected to drive the worldwide HCG market forward. According to the Frisco Institute of Reproductive Medicine, the polycystic ovarian syndrome affects about 10% of women of reproductive age in the United States. The cheap availability of options to treat infertility, on the other hand, could be a possible impediment to market growth.This contributes to the growth of the Global Human Chorionic Gonadotropic    market.

Side Effects of HCG therapy is likely to hamper the market growth

HCG therapy can cause blood clot in patients. Ovarian hyperstimulation syndrome has developed in some women who have used this therapy (OHSS).It causes early puberty in young boys and increases the chances of multiple pregnancy.Also, the FDA has issued cautions regarding the potential harmful effects of utilizing human chorionic gonadotropin (HCG) as a treatment, which is predicted to stifle the market's growth shortly.

COVID-19 Impact Analysis                                                                                          

COVID-19 has had a serious impact on the human chorionic gonadotropic  market. The manufacturing and selling were severely affected during the lockdown, and the major companies were imposed with several restrictions. The manufacturing of the devices came to a halt, and the companies faced major losses

Human Chorionic Gonadotropic Market Segment Analysis

The female infertility treatment segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)     

Infertility is a couple's inability to conceive or a woman's inability to carry a pregnancy to term. After the embryo is formed, human chorionic gonadotropin (HCG) plays an important function. As a result, the use of HCG in the treatment of infertility has gained popularity among both men and women. Over the forecast period, the growing global burden of infertility is expected to drive market expansion. At least 50 million couples worldwide suffer from infertility, according to the Maternal Health Task Force (MHTF). PCOS is female infertility, affecting 6 percent to 12 percent of reproductive-age women in the United States (up to 5 million). Infertility is a severe health problem that affects around 8%–10% of couples worldwide. Infertility affects 60–80 million couples globally each year, with India accounting for between 15 and 20 million (25 percent). According to a World Health Organization (WHO) research, infertility affects one out of four couples in underdeveloped countries.

The availability of various strengths and dosages for individual therapy is expected to drive significant growth in recombinant human chorionic gonadotropin products. Furthermore, due to new goods and widespread usage, demand for naturally derived HCG hormone products is increasing.

Human Chorionic Gonadotropic Market Geographical Share

North America region holds the largest market share of Global Human Chorionic Gonadotropic Market

North America is the largest regional contributor to the market and is expected to remain so in the forecast years. This is primarily due to an increase in the number of infertility cases and hormonal dysfunction in young males and females due to changing lifestyles. According to the Mayo Clinic, approximately 25% of women's fertility problems in the United States are caused by ovulation problems, mostly caused by human chorionic gonadotropin (HCG) hormone dysfunction. The rapid expansion can be attributable to well-established healthcare infrastructure, good reimbursement rules, and the rising cost of infertility. According to the Centers for Disease Control and Prevention, roughly 10% of women in the United States, or 6.1 million women between 15 and 44, have trouble getting pregnant or staying pregnant. As a result of the rapidly increasing infertility cases, the North American global human chorionic gonadotropin market is expected to boom.

However, The Asia Pacific is expected to be the fastest-growing geography, owing to economic developments facilitating technological advancements in healthcare sectors and emerging local market players.

Human Chorionic Gonadotropic Market Companies and Competitive Landscape

The human chorionic gonadotropic market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck and Co.,Merck KGaA, Fresenius SE & Co.KGaA, Lupin Limited, Sanzyme,Intas Pharmaceuticals, Minerva BC(Lee Biosciences), Sun Pharmaceutical Industries Limited, Cigna,Prospec –Tany Technogene Ltd, Scripps Laboratories,Ferring B.V.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance, Acris Antibodies used recombinant DNA technology to create a human chorionic gonadotropin hormone that helps prevent the ovary's disintegration of the corpus luteum, thereby maintaining progesterone production levels for a healthy pregnancy in females.

Lupin Limited

Overview: Lupin Limited is an Indian multinational pharmaceutical corporation headquartered in Mumbai, Maharashtra. It is one of the world's largest generic pharmaceutical companies in revenue. Pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis are among the company's key focus areas.

Product Portfolio:

Lupi-HCG 5000:  Lupi-HCG 5000 Injection is used to treat female infertility. Lupi-HCG can also treat male hypogonadism (delayed puberty and low sperm count). It works by causing eggs to be released from the ovary in women and increasing testosterone levels in men.